Price
No data yet.
Social Signal Score
Revenue
$673.25M+71.48%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kevin J. McNamara
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 15,811
- Beta
- 0.51
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 10.55
Financials
Revenue
$673.25M+71.5%Net Income
$67.70M+152.4%EBITDA
$101.42M+90.6%Free Cash Flow
$69.29M+53.4%EPS (diluted)
$5.13+216.7%Shares Outstanding (diluted)
13.42M-18.9%Operating Expenses
$115.20MCash & Debt
$40.22MReturn of Capital
$105.36MRevenue by Segment (annual)
$2.63BDividend per Share
$0.70Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.53B | $265.24M | $18.42 |
| 2024 | $2.43B | $302.00M | $20.10 |
| 2023 | $2.26B | $272.51M | $18.11 |
| 2022 | $2.13B | $249.62M | $16.72 |
| 2021 | $2.14B | $268.55M | $17.14 |
| 2020 | $2.08B | $319.47M | $20.02 |
| 2019 | $1.94B | $219.92M | $13.77 |
| 2018 | $1.78B | $205.54M | $12.80 |
| 2017 | $1.67B | $98.18M | $6.11 |
| 2016 | $1.58B | $108.74M | $6.64 |
| 2015 | $1.54B | $110.27M | $6.54 |
| 2014 | $1.46B | $99.32M | $5.79 |
| 2013 | $1.41B | $77.23M | $4.24 |
| 2012 | $1.43B | $89.30M | $4.72 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from CHE's reported EPS growth of 11.0% a year over 13 years.
- EPS in 5 years
- $31.04
- Implied price
- $713.96
- Return from $519.84
- 6.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $354.97 — -31.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 20 | 23 | 26 | 29 |
|---|---|---|---|---|---|
| 1.0% | -8.7% | -5.7% | -3.0% | -0.6% | 1.6% |
| 6.0% | -4.2% | -1.1% | 1.8% | 4.3% | 6.6% |
| 11.0% | 0.3% | 3.6% | 6.6% | 9.2% | 11.6% |
| 16.0% | 4.8% | 8.3% | 11.4% | 14.1% | 16.6% |
| 21.0% | 9.3% | 12.9% | 16.2% | 19.0% | 21.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
80+0.00%Social Signal Score
Mentions (2)
- News (RSS)fool·8h ago·Negative
Chemed Executive Spencer Lee Sells 1,000 Shares for $541,040 The insider sold 1,000 shares but still holds nearly 14,000 shares.
View source ↗ - Newsfool.com·12h ago·Negative
Chemed Executive Spencer Lee Sells 1,000 Shares for $541,040 The sale occurred on Aug. 21 and was valued at approximately $541,000. The disposition reduced the executive's direct equity holdings by 7%.
View source ↗
Earnings
Tue, Oct 27(in 7 weeks)
Consensus estimate $6.48 per share
Typical surprise +0.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 28$6.06 vs $5.60beat
- Thu, Apr 23$5.65 vs $5.30beat
- Wed, Feb 25$6.42 vs $7.02miss
- Tue, Oct 28$5.27 vs $5.39miss
- Tue, Jul 29$4.27 vs $4.78miss
- Wed, Apr 23$5.63 vs $5.55beat
Estimates and results for CHE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CHE officers and directors.
- Bought
- $83k
- Sold
- $18.4m
1 trade
21 trades
- Lee Spencer Ssold
- Mcnamara Kevin Jsold
- Mcnamara Kevin Jsold
- Grace Patrick Psold
- Lindell Andrea Rsold
- Walsh George J Iiisold
- Grace Patrick Psold
- Mcnamara Kevin Jsold
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.